Pfizer and Eisai voice "serious concerns" following NICE Alzheimer's review
This article was originally published in Scrip
Executive Summary
The model used by the UK's National Institute for health and Clinical Excellence (NICE) to decide if certain drugs should be used to treat mild stage Alzheimer's disease contains "significant errors", Pfizer and Eisai have claimed.